Please use this identifier to cite or link to this item:
|Title:||A small molecule inhibitor of NF-κB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells|
|Authors:||Lui, VWY;Tsao, SW;Wong, JHT;Umezawa, K;Ho, Y;Wong, EYL;Ng, MHL;Cheng, SH;Tsang, CM;Chan, ATC|
|subject:||Anti-invasion;Anti-proliferation;Apoptosis;DHMEQ;Nasopharyngeal carcinoma;NF-κB inhibitor|
|Publisher:||Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet|
|Description:||Despite the demonstrated constitutive activation of NF-κB in nasopharyngeal carcinoma (NPC), the therapeutic potential of targeting this pathway has not been investigated. Here, we employed a small molecule inhibitor of NF-κB, DHMEQ (which mainly blocks nuclear translocation of activated NF-κB) and demonstrated significant inhibition of NPC cell proliferation, migration, invasion, as well as anchorage-independent growth. These antitumor effects were associated with induction of G 2/M cell cycle arrest and apoptosis, and downregulation of NF-κB target genes (EGFR, cyclin D1 and survivin). This first demonstration of therapeutic benefits of NF-κB targeting in NPC implicates the importance of targeting this pathway in NPC. © 2009 Elsevier Ireland Ltd. All rights reserved.|
|Standard no:||Cancer Letters, 2010, v. 287 n. 1, p. 23-32|
|Appears in Collections:||Department of Anatomy|
Files in This Item:
Click on the URI links for accessing contents.
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.